Skip to main content
BALAXI PHARMACEUTICALS LIMITED logo

BALAXI PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · BALAXI ISIN · INE618N01022 LEI · 894500VRENAYIIWHHQ13 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 615 across all filing types
Latest filing 2026-01-07 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BALAXI

About BALAXI PHARMACEUTICALS LIMITED

https://www.balaxipharma.in/

Balaxi Pharmaceuticals Limited is a specialty pharmaceutical company that operates an asset-light business model focused on sourcing, branding, and distributing generic formulations in frontier markets. The company primarily serves emerging economies across Africa and Latin America, including Angola, Guatemala, and the Dominican Republic. Its product portfolio encompasses a wide range of therapeutic segments such as anti-infectives, analgesics, and antimalarials. Balaxi manages an integrated supply chain, leveraging its regulatory expertise to register and market high-quality pharmaceutical products. By maintaining a robust distribution network and localized presence, the company ensures the availability of essential medicines in underserved regions while optimizing operational efficiency through its specialized procurement and logistics framework.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document text is extremely short (131 characters) and consists solely of a digital signature by an individual named Mohith Kumar Khandelwal, with no substantive content, financial data, or report information. There is no indication of a report, announcement, or any detailed filing. Given the lack of content and the presence of a digital signature, this is likely an officer certification or attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2026-01-07 English
Trading Window
Regulatory Filings Classification · 100% confidence The document text is extremely short (104 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category for miscellaneous filings without substantive content.
2025-12-29 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and is addressed to the National Stock Exchange of India. It explicitly states it is an Investor Presentation on highlights of the financial results for the quarter ended September 30, 2025. The content includes corporate snapshot, financial highlights, strategic roadmap, market presence, manufacturing facilities, corporate structure, board of directors, and leadership team details. There is no indication that this is a full financial report or an announcement of a report publication. The document length is substantial (15,000 characters), and it contains detailed presentation material rather than just a brief announcement or certification. Therefore, it fits the category of an Investor Presentation (IP).
2025-11-14 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a detailed credit rating rationale issued by CRISIL Ratings Limited for Balaxi Pharmaceuticals Limited. It includes a reaffirmation of the credit rating, revision of outlook, detailed financial analysis, key rating drivers, financial indicators, and annexures related to the rating. The document is dated November 13-14, 2025, and contains substantive financial data and analysis, including operating income, profit after tax, debt ratios, and outlook commentary. It is not a brief announcement or a certification letter but a comprehensive rating report. The content aligns with a detailed credit rating report rather than a simple announcement or regulatory filing. Given the nature of the document, it fits best under the category of Regulatory Filings (RNS) because it is a credit rating rationale, which is a regulatory disclosure but not a financial report like an annual or interim report. However, since the document is a rating rationale and not a financial report or earnings release, and given the absence of a more specific category for credit rating rationales, the fallback category Regulatory Filings (RNS) is appropriate with high confidence.
2025-11-14 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding the publication of a newspaper advertisement disclosing the financial results of the company for the quarter and half year ended 30.09.2025. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and 47, which pertain to disclosure requirements. The document includes mention of financial results but does not contain detailed financial statements or substantive financial data itself; rather, it encloses copies of newspaper advertisements and states that the information is also hosted on the company's website. The document length is about 15,000 characters, but the content is primarily an announcement of the publication of financial results in newspapers, not the financial report itself. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of a report rather than the report itself. Hence, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2025-11-12 English
Updates
Interim / Quarterly Report Classification · 85% confidence The document is a formal stock exchange filing under SEBI LODR, reporting the outcome of a board meeting in which the Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and includes substantive financial data (detailed P&L line items) and limited review reports. It is more than a mere announcement (“is attached”) and contains actual financial statements for a period shorter than a fiscal year, fitting the category for an Interim/Quarterly Report (IR). H1 2025
2025-11-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.